Cargando…

First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study

BACKGROUND: In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India). MATERIALS AND METHODS: A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to Novem...

Descripción completa

Detalles Bibliográficos
Autores principales: Akyüz, Ali Rıza, Konuş, Ali Hakan, Çırakoğlu, Ömer Faruk, Şahin, Sinan, Kul, Selim, Korkmaz, Levent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512594/
https://www.ncbi.nlm.nih.gov/pubmed/34643745
http://dx.doi.org/10.1007/s00059-021-05069-4
_version_ 1784583032152260608
author Akyüz, Ali Rıza
Konuş, Ali Hakan
Çırakoğlu, Ömer Faruk
Şahin, Sinan
Kul, Selim
Korkmaz, Levent
author_facet Akyüz, Ali Rıza
Konuş, Ali Hakan
Çırakoğlu, Ömer Faruk
Şahin, Sinan
Kul, Selim
Korkmaz, Levent
author_sort Akyüz, Ali Rıza
collection PubMed
description BACKGROUND: In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India). MATERIALS AND METHODS: A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study. RESULTS: The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days. CONCLUSION: Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves. VIDEO ONLINE: The online version of this article contains a video. The article and the video are available online (10.1007/s00059-021-05069-4). The video can be found in the article back matter as “Electronic Supplementary Material”.
format Online
Article
Text
id pubmed-8512594
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-85125942021-10-13 First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study Akyüz, Ali Rıza Konuş, Ali Hakan Çırakoğlu, Ömer Faruk Şahin, Sinan Kul, Selim Korkmaz, Levent Herz Original Articles BACKGROUND: In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India). MATERIALS AND METHODS: A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study. RESULTS: The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days. CONCLUSION: Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves. VIDEO ONLINE: The online version of this article contains a video. The article and the video are available online (10.1007/s00059-021-05069-4). The video can be found in the article back matter as “Electronic Supplementary Material”. Springer Medizin 2021-10-13 2022 /pmc/articles/PMC8512594/ /pubmed/34643745 http://dx.doi.org/10.1007/s00059-021-05069-4 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Articles
Akyüz, Ali Rıza
Konuş, Ali Hakan
Çırakoğlu, Ömer Faruk
Şahin, Sinan
Kul, Selim
Korkmaz, Levent
First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
title First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
title_full First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
title_fullStr First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
title_full_unstemmed First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
title_short First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
title_sort first experiences with a new balloon-expandable myval transcatheter aortic valve: a preliminary study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512594/
https://www.ncbi.nlm.nih.gov/pubmed/34643745
http://dx.doi.org/10.1007/s00059-021-05069-4
work_keys_str_mv AT akyuzalirıza firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy
AT konusalihakan firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy
AT cırakogluomerfaruk firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy
AT sahinsinan firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy
AT kulselim firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy
AT korkmazlevent firstexperienceswithanewballoonexpandablemyvaltranscatheteraorticvalveapreliminarystudy